ClinicalTrials.gg
CompletedNCT02240433Updated Feb 5, 2020

A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)

A Phase 1 interventional study of LY2157299 and Sorafenib in Hepatocellular Carcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Hepatocellular · Eli Lilly and Company.

Enrollment
10th of 13
9 · median 47
Started
2014
with 2 others
Phase 1
4 of 13
none open now
Registered
8th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 1, and was the 8th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

None of the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company is open now. The open studies under Carcinoma, Hepatocellular, anywhere →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Carcinoma, Hepatocellular by Eli Lilly and Company as a file.
02

Study summary

The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have histological evidence of a diagnosis of HCC (except HCC with fibrolamellar or mixed histology) not amenable to curative surgery.
  • Have Class A.
  • Have the presence of measurable or evaluable lesion as defined by the (RECIST) v1.1. A measurable or evaluable lesion showing demonstrable progression after locoregional therapy could be also included.
  • Have not received sorafenib prior to enrollment.
  • Have resolution to Grade less than or equal 1 by the National Cancer Institute (NCI) (CTCAE) version 4.03 of all toxic effects of prior locoregional therapy, surgery, chemoembolization, systemic chemotherapy.
  • Have a performance status of less than or equal 1 on the (ECOG) scale.

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled, or discontinued within 28 days prior to enrollment from, a clinical trial involving an product or nonapproved use of a drug or device (other than the investigational product used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
  • Have undergone major surgery within 28 days prior to enrollment.
  • Have undergone hepatic locoregional therapy (including radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, cryoablation, percutaneous ethanol injection, or percutaneous microwave coagulation therapy) within 28 days prior to enrollment.
  • Have moderate or severe cardiac disease.

    • Myocardial infarction within 6 months prior to enrollment, unstable angina pectoris, (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension.
    • Documented major (ECG) abnormalities at the investigator's discretion within 28 days prior to enrollment.
    • Major abnormalities documented by echocardiography with Doppler at investigator's direction within 28 days prior to enrollment.
    • Have persistently elevated brain natriuretic peptide (BNP) or elevated troponin I within 14 days prior to enrollment.
    • Predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress.
    • Have a history of cardiac or aortic surgery.
  • Have undergone liver transplant.
  • Are pregnant or breastfeeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    LY2157299 + Sorafenib

    LY2157299 will be administered orally twice daily for 14 days, followed by 14 days with no study drug per 28-day cycle. Sorafenib will be administered orally twice daily for 28 days, in each cycle.

    Drug: LY2157299 · Drug: Sorafenib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT)

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Plasma Concentration-time Curve (AUC) of LY2157299

    Time frame: Cycle 1 Day1: predose through 6 hours post dose; Cycle1 Day14: predose through 24 hours post dose

  2. PK: Maximum Observed Plasma Concentration (Cmax) of LY2157299

    Time frame: Cycle 1 Day 1: Predose through 6 hours post dose; Cycle 1 Day 14: Predose through 24 hours post dose

  3. Time to Progression (TTP)

    Time frame: Baseline to objective progressive disease (estimated as 6 months)

  4. Progression-free Survival (PFS)

    Time frame: Baseline to objective progressive disease or death (estimated as 6 months)

  5. The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD)

    Time frame: Baseline to objective progressive disease (estimated as 6 months)

07

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 277 8577, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kanagawa, 241-8515, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suita-shi, 565-0871, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jul 2017, 32 months.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 32 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Sep 15, 2014
StartActual
Nov 12, 2014
Primary completionActual
Jul 19, 2017
CompletionActual
Dec 25, 2019
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02240433
Responsible party
Sponsor
First posted
Sep 15, 2014
Start date
Nov 12, 2014
Primary completion
Jul 19, 2017
Completion
Dec 25, 2019
Last update
Feb 5, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY-2157299

Start the discussion